Last Updated on October 15, 2024 by The Health Master
Bristol Myers Squibb Co said on Friday that U.S. regulators approved the first drug in a new class of cancer immunotherapies as an initial treatment for advanced melanoma, the deadliest form of skin cancer.
The company said it expects the treatment to eventually garner annual sales of more than $4 billion.
The U.S. Food and Drug Administration (USFDA) approved relatlimab from a class known as LAG-3 inhibitors – short for lymphocyte-activation gene 3 – for use in combination with Bristol’s blockbuster immunotherapy Opdivo as an initial treatment for advanced melanoma.
Double MBA Degree from IU Germany and London South Bank University (LSBU) UKRelatlimab, which will be sold under the brand name Opdualag, more than doubled the time it took for advanced melanoma to worsen compared with Opdivo alone in clinical trials, a measure known as progression-free survival.
The medicine is Bristol Myers’ third approved cancer immunotherapy – drugs that enlist the body’s defenses in the fight against tumors. Opdivo targets a protein called PD-1. Yervoy, the drugmaker’s first such drug, is a CTLA-4 inhibitor.
Relatlimab will only be used in combination with Opdivo, Chief Medical Officer Samit Hirawat said in an interview.
Hirawat said LAG-3 inhibitors like relatlimab can reinvigorate the immune system by restoring the function of “exhausted” T cells – a key component of the immune system – which could improve Opdivo’s performance.
“Our hypothesis is that the best applicability of a LAG-3 inhibitor will be in combination with a PD-1 inhibitor” like Opdivo, he said.
The company expects to charge $27,389 for the combination.
Bristol Myers said it expects the combination therapy to generate sales in excess of $4 billion a year by 2029.
Bristol Myers is testing the combination of Opdivo and relatlimab in other tumor types including colorectal, lung and kidney cancer.
USFDA approves first generic of Symbicort to treat Asthma and COPD
USFDA gives nod to Lupin for Vigabatrin for Oral Solution
USFDA gives tentative nod to Alembic for Macitentan Tablets 10 mg
USFDA gives final nod to Zydus for Colestipol Hydrochloride tablets
USFDA gives nod to Strides Pharma for Colchicine tablets
USFDA gives nod to Alembic Pharmaceuticals for anti fungal drug
US Pharmacopeia report finds high reliance on Indian manufacturers for APIs
19 Indian Pharma Companies get licence to make Pfizer’s oral generic
USFDA approves first generic of Symbicort to treat Asthma and COPD
Govt selects 3 Agencies to conduct study in Pharma and Medical…
USFDA gives nod to Lupin for Vigabatrin for Oral Solution
Availability of drugs at reasonable price: NPPA
Medical Device testing on patients not soon
Demand for framing of statutory working rules in Pharma industry
Drug recall: Fresenius Kabi recalled Sodium Acetate Injection, USP Due to…
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
